Literature DB >> 20581692

Photo essay. MRI and positron emission tomography findings in Heidenhain variant Creutzfeldt-Jakob disease.

Sashank Prasad1, Edward B Lee, John H Woo, Abass Alavi, Steven L Galetta.   

Abstract

The typical presentation of Heidenhain variant Creutzfeldt-Jakob disease (CJD) is a rapidly progressive visual loss in the setting of a relatively normal ophthalmologic examination. At presentation, patients with this uniformly fatal illness frequently demonstrate only minor cortical abnormalities on MRI. Here, we document the clinical presentation and imaging results of a patient with Heidenhain variant CJD in whom abnormalities on positron emission tomographic imaging were more evident than changes on MRI. These changes were present in striate cortex and visual association areas, providing clinical-anatomical correlation with our patient's visual deficits. Nuclear imaging provides a considerably more sensitive measure of neural dysfunction early in the course of this disease.

Entities:  

Mesh:

Year:  2010        PMID: 20581692     DOI: 10.1097/WNO.0b013e3181e2aef7

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  3 in total

1.  Glucose metabolism in sporadic Creutzfeldt-Jakob disease: a statistical parametric mapping analysis of (18) F-FDG PET.

Authors:  E-J Kim; S-S Cho; B-H Jeong; Y-S Kim; S W Seo; D L Na; M D Geschwind; Y Jeong
Journal:  Eur J Neurol       Date:  2011-11-04       Impact factor: 6.089

2.  Creutzfeldt-Jakob disease presenting with visual symptoms: a case of the 'Heidenhain variant'.

Authors:  Rajesh Verma; Vivek Junewar; Ritesh Sahu
Journal:  BMJ Case Rep       Date:  2013-01-29

3.  Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings.

Authors:  Simone Baiardi; Sabina Capellari; Anna Ladogana; Silvia Strumia; Mario Santangelo; Maurizio Pocchiari; Piero Parchi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.